Zydus Lifesciences Limited (NSE: ZYDUSLIFE)
India
· Delayed Price · Currency is INR | Market Cap | 954.97B |
| Revenue (ttm) | 214.84B |
| Net Income (ttm) | 43.03B |
| Shares Out | 1.01B |
| EPS (ttm) | 42.65 |
| PE Ratio | 22.38 |
| Forward PE | 20.97 |
| Dividend | 3.00 (0.32%) |
| Ex-Dividend Date | Jul 26, 2024 |
| Volume | 295,383 |
| Open | 942.20 |
| Previous Close | 944.05 |
| Day's Range | 939.60 - 952.00 |
| 52-Week Range | 628.10 - 1,324.30 |
| Beta | 0.42 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 14, 2024 |
About Zydus Lifesciences
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers finished dosage human formulations, such as generics; branded generics; specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; animal healthcare products; and products in the therapeutic areas of pain management... [Read more]
Financial Performance
In 2023, Zydus Lifesciences's revenue was 195.47 billion, an increase of 13.40% compared to the previous year's 172.37 billion. Earnings were 38.60 billion, an increase of 96.88%.
Financial StatementsNews
Zydus Lifesciences faces setback as SC denies interim relief in breast cancer drug case, sends matter back to Delhi HC
Shares of Zydus Lifesciences were under focus after the Supreme Court refused to grant interim relief to the company in a high-profile breast cancer drug patent case. The SC sent the case back to the ...
Zydus Lifesciences’s market cap gains Rs 1,363 crore as stock surges 1.43%
Shares of Zydus Lifesciences Limited saw a modest rise, closing at ₹963.30, a 1.43% increase from the previous close of ₹949.75. This increase led to a gain of around ₹1,363.45 crore in the company’s ...
Zydus Lifesciences Ltd (BOM:532321) Q2 2025 Earnings Call Highlights: Strong Revenue Growth ...
Zydus Lifesciences Ltd (BOM:532321) Q2 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Regulatory Challenges
Zydus Lifesciences stock drops 2% on Q2 results
Shares of Zydus Lifesciences fell more than 2% following the release of its Q2 financial results. The company’s total revenue saw a sharp decline of 41.39% quarter-on-quarter (QoQ) to ₹492.9 crore, th...
Zydus Lifesciences Q2 FY25: Revenue up 20% YoY to Rs 5237 crore, Net Profit up 13.7% YoY
Zydus Lifesciences posted a strong performance for the quarter ending September 30, 2024 (Q2 FY25), with robust growth across key financial metrics on a year-over-year (YoY) basis. Net Profit: The com...
Q2 results today: Hyundai Motor India, Bosch, Zydus Lifesciences, Nykaa, Unno Minda, 3M India, Natco Pharma, TBO Tek among companies to announce earnings
A diverse group of companies, including Hyundai Motor India, Bosch, Zydus Lifesciences, and FSN E-Commerce Ventures (Nykaa), are set to announce their Q2 FY24-25 financial results today. Here’s a list...
Zydus Lifesciences receives WHO approval for ZyVac® TCV, making it eligible for UN procurement
Zydus Lifesciences Limited has received in-principle acceptability from the World Health Organization (WHO) for its indigenously developed typhoid conjugate vaccine, ZyVac® TCV, making it eligible for...
Zydus Lifesciences gets USFDA approval for Fludrocortisone Acetate tablets
Zydus Lifesciences Limited has recently announced exchanges that the company received final approval from the United States Food and Drug Administration (USFDA) for the manufacture of Fludrocortisone ...
Zydus Lifesciences shares decline nearly 3% after Exelixis wins patent ruling over MSN Labs’ Cabometyx copies – Know More
Zydus Lifesciences shares fell nearly 3% in Wednesday’s early trade after a U.S. federal judge ruled in favor of Exelixis Inc. in a patent dispute over Cabometyx, a blockbuster cancer drug. MSN Labora...
Zydus and ICMR initiate Phase 2 trial of Desidustat for Sickle Cell Disease
Zydus Lifesciences Limited and the Indian Council of Medical Research (ICMR) have commenced a Phase 2 proof-of-concept clinical trial for Desidustat in patients with Sickle Cell Disease (SCD). This tr...
Zydus Lifesciences receives USFDA approval for Paliperidone Extended-Release tablets
Zydus Lifesciences Limited has recently informed exchanges that the company received final United States Food and Drug Administration (USFDA) approval to manufacture Paliperidone Extended-Release Tabl...
Stocks to Watch on Oct 3: Reliance Power, Ashoka Buildcon, CESC, SMS Pharma, PVR INOX, Zydus Lifesciences, Reliance Infra, and HealthCare Global in focus
Key stocks to watch include Ashoka Buildcon, CESC, SMS Pharmaceuticals, PVR INOX, HealthCare Global Enterprises, Zydus Lifesciences, Reliance Power, Reliance Infra, Vikas Lifecare, Eraaya Lifespaces, ...
Zydus Lifesciences gets tentative approval from USFDA for Enzalutamide Tablets, 40 mg and 80 mg
Zydus Lifesciences Limited has recently informed exchanges that the company has received tentative approval from the United States Food and Drug Administration (USFDA) to manufacture Enzalutamide Tabl...
Zydus receives EIR from USFDA for transdermal manufacturing facility
Zydus Lifesciences Limited announced that it has received an Establishment Inspection Report (EIR) from the USFDA for its transdermal patch manufacturing facility located at Pharmez, Ahmedabad. The in...
CDRI finds protein-drug combo to treat osteoporosis induced by chronic kidney disease
After five years of research, CDRI discovers a promising protein-drug combo targeting osteoporosis induced by chronic kidney disease, partnering with Zydus Lifesciences to improve patient care.
Zydus receives USFDA approval for Enzalutamide Capsules
Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Enzalutamide Capsules, 40 mg. These capsules are used in the treatment of meta...
Zydus Lifesciences secures licensing and supply agreement for MRI contrast agents in the US
Zydus Lifesciences announced today that its wholly owned subsidiary, Zydus Lifesciences Global FZE, has entered into an exclusive licensing and supply agreement with Vivit Pharmaceuticals (Vivit).
Stocks to Watch: Reliance, Zydus Lifesciences, ONGC in focus today (Sept 11, 2024)
In today’s market, several stocks are expected to draw attention due to notable developments across various sectors. Stocks in the Green: Reliance Industries: Reliance Retail has entered into a 50/50 ...
Zydus Lifesciences completes its Phase II(a) clinical trial of Usnoflast
Zydus, a leading discovery-based, global pharmaceutical company, has informed exchanges that the company has completed its Phase II(a) clinical study of NLRP3 inhibitor ‘Usnoflast (ZYIL1)’ in patients...
Zydus, Cipla, Lupin, Divi’s: Pharma stocks surge after US House of Representatives passes Biosecure Act
Pharma stocks saw a significant uptick in early trading after the US House of Representatives passed the Biosecure Act, which aims to bolster the pharmaceutical supply chain and encourage domestic dru...
Zydus Lifesciences shareholders approve Rs. 3 per share dividend
At the 29th Annual General Meeting of Zydus Lifesciences Limited, held virtually on August 9, 2024, shareholders approved a dividend of Rs. 3 per share for the financial year 2023-24. This represents ...
Zydus Lifesciences gets warning letter from USFDA for injectables manufacturing facility at Jarod
Zydus Lifesciences informed exchanges on Tuesday that it has received a warning notice from the USFDA regarding its injectables manufacturing facility at Jarod near Vadodara. The USFDA’s Warning Lette...
Zydus’ injectables mfg plant gets USFDA warning letter
Zydus Lifesciences' injectables manufacturing plant in Jarod near Vadodara receives a warning letter from USFDA for violations of manufacturing regulations. No data integrity issues reported.
Zydus Lifesciences gets warning letter from USFDA relating to its injectables manufacturing facility in Jarod
Zydus Lifesciences recently informed the exchanges that the USFDA issued a warning letter regarding its injectables manufacturing facility in Jarod, near Vadodara. The warning letter details violation...
Zydus Lifesciences receives US FDA approval for Scopolamine Patch, eyeing $69.6 Million US Market
Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as “Zydus”) has received final approval from the United States Food and Drug Administration (USFDA) to market S...